This study compares the probability of disease progression, progression-free survival, and overall survival between @entity1 undergoing an allogeneic or autologous transplant for @entity1582 using an identical preparative regimen. @entity1 received a preparative regimen of @entity131 , @entity1863 , and @entity786 followed by an allogeneic or autologous transplant. In the allogeneic group (n = 21), six @entity1 received bone marrow and 15 received @entity1261 mobilized PBSC; all autologous @entity1 (n = 35) received PBSC mobilized with @entity786 and @entity1261 . Allogeneic donors were HLA-identical (n = 20) or one-antigen mismatched (n = 1) siblings. @entity2132 ( @entity2132 ) prophylaxis consisted of @entity1140 (n = 10), @entity1140 / @entity1499 (n = 6), @entity205 / @entity1499 (n = 4), or @entity205 (n = 1). The groups were evenly matched for gender, pretransplant therapy, disease status at time of transplant, @entity1582 subtype, and time from diagnosis to transplant. The median age was significantly lower in the allogeneic group (48 vs 55 years, P < 0.01). In the allogeneic group the probabilities of developing acute @entity2132 grade II-IV and chronic @entity2132 were 55% and 82%, respectively. The Kaplan-Meier probability of disease progression was significantly lower in the allogeneic group (11% vs 64%, P < 0.001) compared to the autologous group. Although progression-free (60% vs 30%, P = 0.19) and overall survival at 2 years (60% vs 42%, P = 0.39) favored the allogeneic group, this did not reach statistical significance. Within the allogeneic transplant group, @entity1 age 50 years or under had a 3-year overall survival significantly higher when compared to older @entity1 (79% vs 29%, P = 0.03). Using identical preparative regimens, allogeneic transplantation reduced disease progression compared to autologous transplantation for @entity1582 . This suggests that allogeneic transplantation induces a @entity2132 ( @entity2132 ) effect.

Allogeneic stem cell transplantation reduces disease progression compared to autologous transplantation in @entity1 with XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity131 :: ('MESH:D001930', 'Disease') :: ['TBI'] @entity1261 :: ('1440', 'Gene') :: ['G-CSF'] @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide'] @entity1582 :: ('MESH:D009101', 'Disease') :: ['multiple myeloma', 'myeloma'] @entity205 :: ('MESH:D016572', 'Chemical') :: ['cyclosporine'] @entity2132 :: ('MESH:D006086', 'Disease') :: ['GVHD', 'graft-versus-myeloma', 'Graft-versus-host disease', 'GVM'] @entity1863 :: ('MESH:D002066', 'Chemical') :: ['busulfan'] @entity1499 :: ('MESH:D008727', 'Chemical') :: ['methotrexate'] @entity1140 :: ('MESH:D016559', 'Chemical') :: ['tacrolimus']
@entity1582 :: (MESH:D009101,Disease) :: ['multiple myeloma']
